FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma
12 affiliations
- 1School of Biochemistry and Biomedical Sciences, University of Bristol, Bristol, United Kingdom
- 2Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
- 3Faculdade de Medicina da Universidade Municipal de São Caetano do Sul, São Caetano do Sul, Brazil
- 4The Wistar Institute, Philadelphia, PA USA
- 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- 6Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan
- 7Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 8Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan
- 9Kindai University Faculty of Medicine, Osakasayama, Japan
- 10Brazilian National Cancer Institute, Rio de Janeiro, Brazil
- 11Department of Molecular Medicine, University of Padova, Padova, 35122 Italy
- 12Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
Abstract
Infection with HTLV-1 can lead to severe diseases, including adult T-cell leukemia/lymphoma (ATL), for which current therapies are inadequate. Selective elimination of chronically infected cells requires identifying cellular markers dysregulated by HTLV-1 that can be exploited therapeutically. Combining metabolomics and proteomics analyses, we identified increased expression of the mitochondrial enzyme ferredoxin reductase (FDXR) as a hallmark of HTLV-1-infected cells. In patient cells, FDXR upregulation mirrored disease severity, was enriched in proliferating tumour cells and predicted worse ATL prognosis. Mechanistically, FDXR upregulation in ATL cells is driven by the transactivating isoforms of two p53 family members, TAp63 and TAp73, and TAp63 expression is, in turn, induced by the IRF4/BATF3 transcriptional axis. In silico drug susceptibility predictions, followed by targeted cytotoxicity, proliferation and Drug-Seq assays demonstrated that FDXR upregulation is associated with increased sensitivity of ATL cells to repurposed chemotherapeutic agents, particularly fluorouracil. Overall, our findings establish FDXR as a novel biomarker of HTLV-1-associated disease progression and ATL prognosis, elucidate its upstream molecular regulation, and highlight its predictive potential for chemotherapeutic sensitivity of ATL cells.
Related
- Prognostic value of circulating cell-free Epstein-Barr virus DNA CpG methylation in extranodal NK/T cell lymphoma
- Long-term remission of chronic-type adult T-cell leukemia/lymphoma associated with Graves’ disease treated with methimazole
- An Exploratory Multiome Analysis of a BCG-Associated HSPC Signature: Trained-Immunity Marker in Blood and an Adverse Prognostic Association in Tumour
- Elevated UHRF1 predicts unfavorable clinical outcomes in adult T-cell leukemia/lymphoma: Clinicopathological analysis and preliminary in vitro observations
- ADULT T-CELL LEUKEMIA/LYMPHOMA IN SUSTAINED COMPLETE RESPONSE SIX YEARS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM A RELATED HTLV-1-POSITIVE DONOR: A CASE REPORT
BibTeX
@article{gallucci2026fdxr,
title = {{FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma}},
author = {Lara Gallucci and Maria Josephine and Yasunori Kogure and Alex Ap Rosini Silva and Vincent Cantaloube-Ferrieu and Marcos Eduardo Souza Abreu and Trusha Ramteke and Phoebe Kibble and Guilherme Lucchesi D Angelo Braz and Rubens de Assis Santos Sebastião and Luiza Amoroso Lambaz and Aijun Lin and Beth Hoare and Felipe Custódio Carvalho dos Santos and Sophie Shackley and Alex Quin and Sofia Luari Moelas Giuzio and Philip A Lewis and Wujuan Zhang and Youko Nukui and Juliana Pereira and Hebert Fabricio Culler and Takuro Kameda and Kazuya Shimoda and Kate Heesom and Aaron R Goldman and Ester Cerdeira Sabino and Seishi Ogawa and Fabio Eudes Leal and Mattia Forcato and Keisuke Kataoka and Sheila de Oliveira Garcia Mateos and Iart Luca Shytaj},
journal = {EMBO Molecular Medicine},
year = {2026},
month = oct,
doi = {10.1038/s44321-026-00535-0},
url = {https://doi.org/10.1038/s44321-026-00535-0},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - FDXR upregulation by p63/p73 is a prognostic and therapeutic marker of adult T-cell leukemia/lymphoma
AU - Lara Gallucci
AU - Maria Josephine
AU - Yasunori Kogure
AU - Alex Ap Rosini Silva
AU - Vincent Cantaloube-Ferrieu
AU - Marcos Eduardo Souza Abreu
AU - Trusha Ramteke
AU - Phoebe Kibble
AU - Guilherme Lucchesi D Angelo Braz
AU - Rubens de Assis Santos Sebastião
AU - Luiza Amoroso Lambaz
AU - Aijun Lin
AU - Beth Hoare
AU - Felipe Custódio Carvalho dos Santos
AU - Sophie Shackley
AU - Alex Quin
AU - Sofia Luari Moelas Giuzio
AU - Philip A Lewis
AU - Wujuan Zhang
AU - Youko Nukui
AU - Juliana Pereira
AU - Hebert Fabricio Culler
AU - Takuro Kameda
AU - Kazuya Shimoda
AU - Kate Heesom
AU - Aaron R Goldman
AU - Ester Cerdeira Sabino
AU - Seishi Ogawa
AU - Fabio Eudes Leal
AU - Mattia Forcato
AU - Keisuke Kataoka
AU - Sheila de Oliveira Garcia Mateos
AU - Iart Luca Shytaj
PY - 2026
DA - 2026/10/12
JO - EMBO Molecular Medicine
DO - 10.1038/s44321-026-00535-0
UR - https://doi.org/10.1038/s44321-026-00535-0
AB - Infection with HTLV-1 can lead to severe diseases, including adult T-cell leukemia/lymphoma (ATL), for which current therapies are inadequate. Selective elimination of chronically infected cells requires identifying cellular markers dysregulated by HTLV-1 that can be exploited therapeutically. Combining metabolomics and proteomics analyses, we identified increased expression of the mitochondrial enzyme ferredoxin reductase (FDXR) as a hallmark of HTLV-1-infected cells. In patient cells, FDXR upregulation mirrored disease severity, was enriched in proliferating tumour cells and predicted worse ATL prognosis. Mechanistically, FDXR upregulation in ATL cells is driven by the transactivating isoforms of two p53 family members, TAp63 and TAp73, and TAp63 expression is, in turn, induced by the IRF4/BATF3 transcriptional axis. In silico drug susceptibility predictions, followed by targeted cytotoxicity, proliferation and Drug-Seq assays demonstrated that FDXR upregulation is associated with increased sensitivity of ATL cells to repurposed chemotherapeutic agents, particularly fluorouracil. Overall, our findings establish FDXR as a novel biomarker of HTLV-1-associated disease progression and ATL prognosis, elucidate its upstream molecular regulation, and highlight its predictive potential for chemotherapeutic sensitivity of ATL cells.
SN - 1757-4676
SN - 1757-4684
ER -